A $46M Bet on a New Way to Treat the Most Common Hereditary Kidney Disease

Jan de Vries · 2026-08-07

A small biotech in Glasgow just secured a massive vote of confidence from some of the biggest names in European healthcare investing. Mironid, a company spun out of Scottish universities, has closed a $46 million Series B round to push its lead drug candidate through clinical trials. The goal? To fundamentally change how we treat a disease that affects millions of people worldwide. This isn't just another funding announcement. It's a signal that the approach Mironid is taking—targeting a specific cellular mechanism that drives kidney cyst growth—might finally offer something better than what's currently on the market. ### Why This Funding Round Matters The round was led by the Scottish National Investment Bank, with participation from existing backers like Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When that caliber of investor doubles down, it's worth paying attention. Neil Wilkie, Mironid's CEO, put it plainly: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60." That's a staggering statistic. Half of the people with this condition will need dialysis or a kidney transplant before they turn 60. The current treatments exist, but they come with significant side effects and don't work for everyone. ### The Science: Targeting the Root Cause Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by mutations in the PKD1 or PKD2 genes. These mutations lead to the uncontrolled growth of fluid-filled cysts in the kidneys. Over time, these cysts crowd out healthy tissue, and the kidneys eventually fail. Mironid's approach is different. Instead of just managing symptoms, their drug candidate targets cyclic AMP (cAMP), a cellular signal that's active at every stage of the disease. This signal drives both the proliferation of cells and the secretion of fluid inside the cysts. Here's what makes this potentially game-changing: - **It tackles the disease at its source**, not just the downstream effects - **Preclinical data shows reductions in both cyst number and kidney volume** - **The mechanism could prevent new cysts from forming while halting growth of existing ones** If those results hold up in human trials, this could mean a more durable treatment option with a better side-effect profile than what's currently available. ### From University Labs to Clinical Trials Mironid's story starts back in 2015, when it was spun out of the University of Strathclyde and Heriot-Watt University. The company builds on over three decades of research into PDE biology by Professor Miles Houslay. That's a long runway of scientific groundwork. The company is headquartered in Glasgow and focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory diseases and cancer. Beyond ADPKD, their pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which play a role in cell signaling pathways linked to disease progression. ### What the Money Will Fund The fresh capital will go toward advancing the clinical development of Mironid's first-in-class LoAc small molecule candidate for ADPKD patients. This is the critical next step—moving from promising preclinical data to proving efficacy and safety in humans. Paul Callaghan, Investment Director at the Scottish National Investment Bank, said: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." It's worth noting this Series B follows an earlier Series A extension round. In total, Mironid has now raised about $47 million since inception. For a company at this stage, that's a solid war chest. ### The Bigger Picture The interest from big pharma and specialist healthcare investors signals a broader trend. Rare diseases are getting more attention because the science is finally catching up to the need. And with the right funding, small companies like Mironid can punch well above their weight. For patients with ADPKD, the hope is that this research translates into a real treatment option that slows disease progression without wrecking their quality of life. That's the ultimate goal. The road ahead is long—clinical trials take years—but this funding round puts Mironid in a strong position to navigate it.